nach oben

Erschienen in:

09.01.2017 | Harnblasenkarzinom | Zertifizierte Fortbildung

Früherkennung, Diagnose, Therapie und Nachsorge

Kurzform der S3-Leitlinie Harnblasenkarzinom

verfasst von: Prof. Dr. med. Margitta Retz, Jürgen E. Gschwend, Philipp Maisch

Erschienen in: Uro-News | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die S3-Leitlinie Harnblasenkarzinom wurde gemeinsam mit dem Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), der Deutschen Krebsgesellschaft und der Deutschen Krebshilfe unter Beteiligung von weiteren 31 medizinischen Fachgesellschaften erstellt. Die Kurzversion soll Auszüge an Empfehlungen aus der S3-Leitlinie Harnblasenkarzinom vorstellen. Die Empfehlungen basieren auf systematischen Literaturrecherchen und Expertenmeinungen und wurden von Blasenkarzinomexperten und Gesellschaften abgestimmt.

Goessl C et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol. 1997;157(2):480–1.PubMedCrossRef

Herranz-Amo F et al. Need for intravenous urography in patients with primary transitional carcinoma of the bladder? Eur Urol. 1999;36(3):221–4.PubMedCrossRef

Palou J et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005;174(3):859–61.PubMedCrossRef

Millan-Rodriguez F et al. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol. 2000;164(4):1183–7.PubMedCrossRef

Van der Molen AJ et al. CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol. 2008;18(1):4–17.CrossRef

Hermann GG et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in T a/T1 patients: a randomized two-centre study. BJU Int. 2011;108(8b):E297–303.PubMedCrossRef

Stenzl A et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907–13.PubMedPubMedCentralCrossRef

Geavlete B et al. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer—re-TURBT recurrence rates in a prospective, randomized study. Urology. 2010;76(3):664–9.PubMedCrossRef

Karaolides T et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology. 2012;80(2):354–9.PubMedCrossRef

10.

Yuan H et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(9):e74142.PubMedPubMedCentralCrossRef

11.

Shen P et al. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int. 2012; 110(6 Pt B):E209–15.PubMedCrossRef

12.

Yang LP. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. Mol Diagn Ther. 2014;18(1):105–116.PubMedCrossRef

13.

Rink M et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624–38.PubMedCrossRef

14.

Böhle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–6.PubMedCrossRef

15.

Sylvester RJ et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–70.PubMedCrossRef

16.

Sylvester RJ et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–73.PubMedCrossRef

17.

Malmstrom PU et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–56.PubMedCrossRef

18.

Shang PF et al. Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011(5):Cd006885.

19.

Fernandez-Gomez J et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423–30.PubMedCrossRef

20.

Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–23.PubMedCrossRef

21.

Shelley MD et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–16.PubMedCrossRef

22.

Shelley MD et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–90.PubMedCrossRef

23.

Gardmark T et al. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int. 2007;99(4):817–20.PubMedCrossRef

24.

Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5.PubMedCrossRef

25.

Friedrich MG et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52(4):1123–29.PubMedCrossRef

26.

Lamm DL et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.PubMedCrossRef

27.

Tilki D et al. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol. 2010;58(1): 112–7.PubMedCrossRef

28.

Gray PJ et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014;88(5):1048–56.PubMedCrossRef

29.

Herr HW et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9.PubMedCrossRef

30.

May M et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol. 2011;18(7):2018–25.PubMedCrossRef

31.

Simone G et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol. 2013;20(4):390–7.PubMedCrossRef

32.

Herr HW et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167(3):1295–8.PubMedCrossRef

33.

Weisbach L et al. Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. Int Urol Nephrol. 2013;45(6):1561–7.PubMedCrossRef

34.

Kitamura H, Masumori N, Tsukamoto T. Role of lymph node dissection in management of bladder cancer. Int J Clin Oncol. 2011;16(3):179–85.PubMedCrossRef

35.

Karl A et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol. 2009;55(4):826–35.PubMedCrossRef

36.

Bi L et al. Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int. 2014;113(5b):E39–48.PubMedCrossRef

37.

Zehnder P et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011;186(4):1261–8.PubMedCrossRef

38.

Koppie TM et al. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006;107(10):2368–74.PubMedCrossRef

39.

Colombo JR Jr, Haber GP, Gill IS. Laparoscopic partial nephrectomy in patients with compromised renal function. Urology. 2008;71(6):1043–8.PubMedCrossRef

40.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 1.1, 2014, AWMF Registrierungsnummer: 021-007OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html [Stand: 11.11.2016]

41.

Millan M et al. Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units. Colorectal Dis 2010;12(7 Online):e88–92.PubMed

42.

Bass EM et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum. 1997;40(4):440–2.PubMedCrossRef

43.

Colwell JC, Gray M. Does preoperative teaching and stoma site marking affect surgical outcomes in patients undergoing ostomy surgery? J Wound Ostomy Continence Nurs. 2007;34(5):492–6.PubMedCrossRef

44.

Chaudhri S et al. Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial. Dis Colon Rectum. 2005;48(3):504–9.PubMedCrossRef

45.

Schwenk W. Moderne perioperative Behandlung. In: Kreis ME, Straßburg J, Hrsg. Moderne Chirurgie des Rektumkarzinoms. Berlin, Heidelberg: Springer; 2015, S. 182–90.

46.

Glatzle J, Longin I, Gruber G. Stomaanlage und Stomatherapie. In: Kreis ME, Straßburg J, Hrsg. Moderne Chirurgie des Rektumkarzinoms. 2015,: Berlin, Heidelberg: Springer; 2015. S. 164–71.

47.

Sternberg CN et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64(12):2448–58.PubMedCrossRef

48.

Mead GM et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer. 1998;78(8):1067–75.PubMedPubMedCentralCrossRef

49.

Von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.PubMed

50.

Bellmunt J et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13.PubMedPubMedCentralCrossRef

51.

Sternberg CN et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19(10): 2638–46.PubMed

52.

Bellmunt J et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61.PubMedCrossRef

53.

Bellmunt J et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466–72.PubMedCrossRef

54.

Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466–5.PubMedCrossRef

55.

National Institute for Health and Care Excellence (NICE) [Internet]. London: The Institute [cited 2016 Nov 11]. Bladder cancer: diagnosis and management. 2015; Available from: https://www.nice.org.uk/guidance/ng2.

Titel: Früherkennung, Diagnose, Therapie und Nachsorge
Kurzform der S3-Leitlinie Harnblasenkarzinom
verfasst von: Prof. Dr. med. Margitta Retz
Jürgen E. Gschwend
Philipp Maisch
Publikationsdatum: 09.01.2017
Verlag: Springer Medizin
Schlagwörter: Harnblasenkarzinom
Harnblasenkarzinom
Urothelkarzinom
Urografie
Urothelkarzinom
Erschienen in: Uro-News / Ausgabe 1/2017
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI: https://doi.org/10.1007/s00092-017-1283-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Kurzform der S3-Leitlinie Harnblasenkarzinom

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

KBV kontra Kliniken: Zwist um Notfälle

Kollegen anstellen: Was beim Arbeitsvertrag zu beachten ist!

Macht Operieren viele Chirurgen krank?

Ihr liebstes Titelbild 2016?

Checkpoint-Inhibitor Nivolumab verlängert das Gesamtüberleben von mRCC-Patienten

5-Alpha-Reduktasehemmer vor TUR-P senkt Blutungsrisiko

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie